Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 5/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.75 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.75 |
| ▸ | HTR3B | O95264 | 2/20 | 0.75 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.75 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.75 |
| ▸ | HTR5A | P47898 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | DRD4 | P21917 | 3/20 | 0.62 |
| ▸ | DRD2 | P14416 | 2/20 | 0.59 |
| ▸ | DRD3 | P35462 | 2/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mezacopride SCHEMBL7278137 | 1.00 | HTR3A (0.75) | HTR3ACYP2D6HTR3EHTR3BHTR3D | |
| Mezacopride SCHEMBL9601284 | 1.00 | HTR3A (0.75) | HTR3ACYP2D6HTR3EHTR3BHTR3D | |
| Mezacopride SCHEMBL1802144 | 1.00 | HTR3A (0.75) | HTR3ACYP2D6HTR3EHTR3BHTR3D | |
| Mezacopride SCHEMBL10517254 | 0.99 | MAPK1 (0.74) | HTR3ACYP2D6HTR3EHTR3BHTR3D | |
| SCHEMBL10690911 | 0.90 | HTR3A (0.74) | HTR3ACYP2D6HTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL7278968 | 0.89 | MAPK1 (0.71) | HTR3ACYP2D6HTR3EHTR3BHTR3D | |
| (R)Zacopride SCHEMBL5387843 | 0.86 | HTR3A (1.00) | HTR3ACYP2D6HTR3EHTR3BHTR3D | |
| Zacopride SCHEMBL5373467 | 0.86 | HTR3A (1.00) | HTR3ACYP2D6HTR3EHTR3BHTR3D | |
| Zacopride SCHEMBL29567897 | 0.86 | HTR3A (1.00) | HTR3ACYP2D6HTR3EHTR3BHTR3D | |
| Zacopride SCHEMBL16003 | 0.86 | HTR3A (1.00) | HTR3ACYP2D6HTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2011126937-A1 | TARGETED INTRACELLULAR DELIVERY OF OLIGONUCLEOTIDES VIA CONJUGATION WITH SMALL MOLECULE LIGANDS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2011-10-13 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-6946141-B2 | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation | VIVUS, INC. (US) | 2005-09-20 | — | — | US | claimed |
| EP-1389115-A2 | AS-NEEDED ADMINISTRATION OF TRICYCLIC AND OTHER NON-SRI ANTIDEPRESSANT DRUGS TO TREAT PREMATURE EJACULATION | Vivus, Inc. (US) | 2004-02-18 | — | — | EP | claimed |
| US-6495154-B1 | ADMINISTERING ANTIDEPRESSANTS, ADRENERGIC STIMULANTS, SEROTONIN AGONISTS AND ANTAGONISTS AS THERAPEUTIC AGENTS FOR SEXUAL DISORDERS | VIVUS INC. | 2002-12-17 | — | — | US | claimed |
| US-20020161016-A1 | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation | VIVUS LLC (F/K/A VIVUS, INC.) | 2002-10-31 | — | — | US | claimed |
| WO-2002041883-A2 | AS-NEEDED ADMINISTRATION OF TRICYCLIC AND OTHER NON-SRI ANTIDEPRESSANT DRUGS TO TREAT PREMATURE EJACULATION | VIVUS, INC. (US) | 2002-05-30 | — | — | WO | claimed |
| US-20010008896-A1 | Administration of active agents, including 5-HT receptor agonists and antagonists, to treat premature ejaculation | SMITH WILLIAM L (US) | 2001-07-19 | — | — | US | claimed |
| US-5922341-A | Local administration of pharmacologically active agents to treat premature ejaculation | VIVUS, INCORPORATED (US) | 1999-07-13 | — | — | US | claimed |
| US-20260077139-A1 | SPACER DEVICE WITH FLOW RATE SPIROMETER | AEROVU TECHNOLOGIES, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4706758-A2 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12514993-B2 | Spacer device with flow rate spirometer | AEROVU TECHNOLOGIES, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-6037360-A | Administration of 5-HT3 receptor antagonists to treat premature ejaculation | VIVUS, INCORPORATED (US) | 2000-03-14 | — | — | US | disclosed |
| US-5922341-A | Local administration of pharmacologically active agents to treat premature ejaculation | VIVUS, INCORPORATED (US) | 1999-07-13 | — | — | US | disclosed |
| WO-1999021508-A1 | ADMINISTRATION OF ACTIVE AGENTS, INCLUDING 5-HT RECEPTOR AGONISTS AND ANTAGONISTS, TO TREAT PREMATURE EJACULATION | VIVUS, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161016-A1 | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation | HTR5A, HTR1A, MAOA | HTR3A 8/4885CYP2D6 347/4885HTR3E 49/4885 |
| US-20260077139-A1 | SPACER DEVICE WITH FLOW RATE SPIROMETER | TMCO1, CFTR, CYSLTR2 | HTR3A 1591/4885CYP2D6 467/4885HTR3E 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.